0001 GMT - Integral Diagnostics gets a new bull at Bell Potter in anticipation of the enhanced scale offered by the imaging provider's merger with Capitol Health. Analyst Martyn Jacobs tells clients in a note that the combined Integral-Capitol business will become Australia's third-largest imaging provider, creating operating leverage and opportunities in telehealth. He says that regulatory changes could allow the group to extend operating hours, generating an additional A$11 million in fiscal 2026 revenue. Bell Potter initiates coverage with a buy rating and A$3.87 target price on the stock, which is up 4.0% at A$3.16. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 04, 2024 19:01 ET (00:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.